

Supplementary Materials

# N1-Benzyl Tryptamine Pan-SHIP1/2 Inhibitors: Synthesis and Preliminary Biological Evaluation as Anti-Tumor Agents

Sandra Fernandes <sup>1</sup>, Shea T. Meyer <sup>2</sup>, Jigisha P. Shah <sup>2</sup>, Arijit A. Adhikari <sup>2</sup>, William G. Kerr <sup>1</sup>  
and John D. Chisholm <sup>2,\*</sup>

<sup>1</sup> Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY 13210, USA



<sup>2</sup> Department of Chemistry, Syracuse University, Syracuse, NY 13244, USA



\* Correspondence: jdchisho@syr.edu



## Contents



Table of Contents	S1
NMR Spectra	S2-S24
Tables of Predicted Pharmacodynamic data	S25



























































































**Table S1. Predicted Physiochemical Properties and Lipophilicity for the Tested Tryptamines<sup>a</sup>**



Entry	Cmpd	R <sup>1</sup>	X	Y	MW	CLogP <sup>b</sup>	TPSA	Molar Refractivity	Number of Rotatable Bonds	H Bond Acceptors	H Bond Donors
1	<b>1</b>	2-chlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	344.9	4.11	56.25	101.86	5	1	1
2	<b>7b</b>	4-chlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	344.9	4.11	56.25	101.86	5	1	1
3	<b>7c</b>	4-bromobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	389.35	4.23	56.25	104.55	5	1	1
4	<b>7d</b>	2,4-dichlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	379.35	4.60	56.25	106.87	5	1	1
5	<b>7e</b>	benzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	310.46	2.10	56.25	96.85	5	1	1
6	<b>7f</b>	H	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	220.33	3.62	67.11	67.47	3	1	2
7	<b>11a</b>	benzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	H	264.36	3.12	30.95	85.13	4	1	1
8	<b>11b</b>	2-chlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	H	298.81	3.62	30.95	90.14	4	1	1
9	<b>13</b>	2-chlorobenzyl	MeNH <sub>2</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	358.93	4.34	42.26	106.77	6	1	1
10	<b>14</b>	2-chlorobenzyl	Me <sub>2</sub> NH <sup>+</sup> Cl <sup>-</sup>	SMe	372.95	4.56	33.47	111.67	6	1	0
11	<b>15</b>	2-chlorobenzyl	NHSO <sub>2</sub> Me	SMe	422.99	3.27	84.78	115.73	7	3	1
12	<b>16</b>	2-chlorobenzyl	NHAc	SMe	386.94	4.01	59.33	111.77	7	1	1
13	<b>17</b>	2-chlorobenzyl	EtNH <sub>2</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	372.95	4.56	42.26	111.57	7	1	1

<sup>a</sup>Calculated using SwissADME.[1] <sup>b</sup>CLogP calculated for the free amine using the MLOGP method[2, 3] with SwissADME.[1]

**Table S2. Predicted Pharmacokinetic Properties for the Tested Tryptamines<sup>a</sup>**



Entry	Cmpd	R <sup>1</sup>	X	Y	ESOL Log S	ESOL Solubility class	GI absorption	BBB permeant	Pgp substrate	CYP1A2 inhibitor	CYP2C19 inhibitor	CYP2C9 inhibitor	log Kp (cm/s)
1	<b>1</b>	2-chlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-4.93	Moderately soluble	High	Yes	Yes	Yes	Yes	Yes	-5.24
2	<b>7b</b>	4-chlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-4.93	Moderately soluble	High	Yes	Yes	Yes	Yes	Yes	-5.24
3	<b>7c</b>	4-bromobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-5.25	Moderately soluble	High	Yes	Yes	Yes	Yes	Yes	-5.47
4	<b>7d</b>	2,4-dichlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-5.52	Moderately soluble	High	Yes	Yes	Yes	Yes	Yes	-5.01
5	<b>7e</b>	benzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-4.35	Moderately soluble	High	Yes	Yes	Yes	Yes	No	-5.47
6	<b>7f</b>	H	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-2.89	Soluble	High	Yes	No	Yes	No	No	-6.03
7	<b>11a</b>	benzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	H	-3.86	Soluble	High	Yes	Yes	Yes	Yes	No	-5.56
8	<b>11b</b>	2-chlorobenzyl	NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup>	H	-4.44	Moderately soluble	High	Yes	Yes	Yes	Yes	No	-5.33
9	<b>13</b>	2-chlorobenzyl	MeNH <sub>2</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-5.26	Moderately soluble	High	Yes	Yes	Yes	Yes	Yes	-4.96
10	<b>14</b>	2-chlorobenzyl	Me <sub>2</sub> NH <sup>+</sup> Cl <sup>-</sup>	SMe	-5.62	Moderately soluble	High	Yes	No	Yes	Yes	Yes	-4.72
11	<b>15</b>	2-chlorobenzyl	NHSO <sub>2</sub> Me	SMe	-5.25	Moderately soluble	High	No	No	Yes	Yes	Yes	-5.69
12	<b>16</b>	2-chlorobenzyl	NHAc	SMe	-5.17	Moderately soluble	High	Yes	No	Yes	Yes	Yes	-5.32
13	<b>17</b>	2-chlorobenzyl	EtNH <sub>2</sub> <sup>+</sup> Cl <sup>-</sup>	SMe	-5.49	Moderately soluble	High	Yes	Yes	Yes	Yes	No	-4.79

<sup>a</sup>Calculated using SwissADME.[1]

## References

1. Daina, A.; Michielin, O.; Zoete, V.; Michielin, O.; Michielin, O. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep* **2017**, 7, 42717. doi:10.1038/srep42717
2. Moriguchi, I.; Hirono, S.; Nakagome, I.; Hirano, H. Comparison of reliability of log P values for drugs calculated by several methods. *Chem. Pharm. Bull.* **1994**, 42, 976. doi:10.1248/cpb.42.976
3. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Delivery Rev.* **1997**, 23, 3-25. doi:10.1016/s0169-409x(00)00129-0